186 related articles for article (PubMed ID: 23860090)
1. Companion diagnostics in oncology - current status and future aspects.
Jørgensen JT
Oncology; 2013; 85(1):59-68. PubMed ID: 23860090
[TBL] [Abstract][Full Text] [Related]
2. Regulatory considerations for companion diagnostic devices.
Lee EY; Shen HC
Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
[TBL] [Abstract][Full Text] [Related]
3. Oncology drug-companion diagnostic combinations.
Jørgensen JT
Cancer Treat Res Commun; 2021; 29():100492. PubMed ID: 34844911
[TBL] [Abstract][Full Text] [Related]
4. DAKO and Bayer to distribute oncology serum assays.
Expert Rev Mol Diagn; 2002 May; 2(3):205. PubMed ID: 12050858
[No Abstract] [Full Text] [Related]
5. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
6. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
7. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
8. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
Jørgensen JT; Hersom M
Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
[TBL] [Abstract][Full Text] [Related]
10. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
11. A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery.
Smith NR; Womack C
J Pathol; 2014 Jan; 232(2):190-8. PubMed ID: 24030847
[TBL] [Abstract][Full Text] [Related]
12. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
Ludwig WD; Schildmann J
Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Predictive markers in early research and companion diagnostic developments in oncology.
Pickl M; Ruge E; Venturi M
N Biotechnol; 2012 Sep; 29(6):651-5. PubMed ID: 22484859
[TBL] [Abstract][Full Text] [Related]
15. FDA perspective on companion diagnostics: an evolving paradigm.
Mansfield EA
Clin Cancer Res; 2014 Mar; 20(6):1453-7. PubMed ID: 24634468
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
17. Qualification of imaging biomarkers for oncology drug development.
Waterton JC; Pylkkanen L
Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
[TBL] [Abstract][Full Text] [Related]
18. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in oncology drug development: a pharma perspective.
Hollingsworth SJ
Drug Discov Today; 2015 Dec; 20(12):1455-63. PubMed ID: 26482740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
